ALIMTA (Pemetrexed) in Patients With Locally Advanced or Metastatic Cancer
Sponsored by Eli Lilly and Company
About this trial
Last updated 20 years ago
Study ID
1310
Status
Completed
Type
Interventional
Phase
Phase 1
Placebo
No
Accepting
18+ Years
All Sexes
What is this trial about?
This is a non-randomized, phase 1, study with the primary objective of determining the toxicities and establishing the maximum tolerated dose of ALIMTA when administered as a 10 minute infusion every 21 days with folic acid or multi-vitamin supplementation therapy in lightly or heavily pre-treated patients with locally advanced or metastatic cancer.
What are the participation requirements?
Inclusion Criteria
* Histologic or cytologic diagnosis of metastatic or locally advanced cancer
* Prior chemotherapy is allowed
* Adequate bone marrow, liver and kidney function
Exclusion Criteria
* Prior treatment with ALIMTA
* Brain metastasis
* Pregnancy or breast feeding